dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:18:01Z
dc.date.accessioned2022-10-05T17:30:30Z
dc.date.available2014-05-27T11:18:01Z
dc.date.available2022-10-05T17:30:30Z
dc.date.created2014-05-27T11:18:01Z
dc.date.issued1995-08-09
dc.identifierArquivos Brasileiros de Cardiologia, v. 64, n. 6, p. 571-575, 1995.
dc.identifier0066-782X
dc.identifierhttp://hdl.handle.net/11449/64629
dc.identifier2-s2.0-0029115889
dc.identifier2-s2.0-0029115889.pdf
dc.identifier7095933557855151
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3914644
dc.description.abstractPurpose. To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension. Methods. Out-patients (n = 471) with mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with 15 days of washout, were included to the treatment initially with half tablet of the association of captopril 50 mg + hydrochlorothiazide 25 mg once daily, for 30 days. After this period, patients with DBP > 90 mmHg had the dosage duplicated, while the others had the same dosage for 60 days more. Evaluation was performed 15 days before and then every month during active drug. Results. Twenty six patients were withdrawn, 13 (2,7%) by adverse effects and 13 by protocol violation. At the end of the wash-out period, the blood pressure (BP), 162 ± 16/103 ± 6 mmHg decreased significantly at the 30th day to 146 ± 14/92 ± 8 mmHg (p < 0,001 vs 0th day); 139 ± 12/86 ± 7 mmHg at the 60th day, (p < 0,001 vs 30th day), and further to 136 ± 11/84 ± 5 mmHg (p < 0,001 vs day 0) till the end of the 90th day. Antihypertensive efficay (DBP ≤ 90 mmHg and decreased for the DBP ≥ 10 mmHg) was obtained in 82% of the patients. There was no difference in BP control considering race, hypertension level, previous antihypertensive treatment and obesity. Cough (4%) was the main adverse event. Conclusion. Captopril + hydrochlorothiazide was effective and safe in the treatment of mild to moderate hypertension. The favorable response was observed in 82% of the patients independently of race, hypertensive level, previous antihypertensive treatment and obesity. Low incidence of side effects was reported, with no difference from others reported in the literature.
dc.languagepor
dc.relationArquivos Brasileiros de Cardiologia
dc.relation1.318
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectangiotensin converting enzyme inhibitor
dc.subjectcaptopril
dc.subjecthydrochlorothiazide
dc.subjectantihypertensive agent
dc.subjectadult
dc.subjectaged
dc.subjectantihypertensive activity
dc.subjectblood pressure
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcoughing
dc.subjectdrug efficacy
dc.subjectdrug tolerance
dc.subjectfemale
dc.subjecthuman
dc.subjecthypertension
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoral drug administration
dc.subjectadolescent
dc.subjectdrug combination
dc.subjectdrug effect
dc.subjectheart rate
dc.subjecthospitalization
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntihypertensive Agents
dc.subjectBlood Pressure
dc.subjectCaptopril
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHeart Rate
dc.subjectHumans
dc.subjectHydrochlorothiazide
dc.subjectHypertension
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectSeverity of Illness Index
dc.titleEFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO
dc.typeArtigo


Este ítem pertenece a la siguiente institución